New Veterinary Medicinal Products Unit fees for 2025
With effect from 1 January 2025, the Medicines Evaluation Board (MEB) will be increasing its fees. This increase is necessary due to wage and price developments. For the Veterinary Medicinal Products Unit (VMPU), the increase will be 8.8%. In addition to this standard increase, there will be an additional increase in the fee for two procedures. The fees that will take effect on 1 January 2025 will be included in the revised Veterinary Medicinal Products Regulations 2022.
The VMPU charges for the work that it performs. For example, fees are charged for the application and change procedures relating to the issuing of marketing authorisations and production and distribution licences for veterinary medicinal products. Marketing authorisation holders also pay an annual fee for each marketing authorisation they hold. Each fee is linked to a product type.
Additional increase for specific procedures
The guiding principle in setting fees is that fees should cover costs. This depends on the average amount of work that needs to be performed for a procedure of a particular type. Based on the average time spent, counting from 2018, an additional increase will be necessary for the following procedures:
|
Product type |
Type of application |
Fee in 2024 |
Fee in 2025 |
|
1030 |
DCP RMS marketing authorisation, generic or hybrid dossier |
€14.854 |
€22.281 |
|
1084 |
CMS VRA-Standard G.I.18 update QRD template 9.0 |
€448 |
€976 |
The VMPU overview of fees and product types lists the current fees as well as the fees that will take effect on 1 January 2025.
More information
If you have any questions as a result of this message, please submit them to the VMPU using our contact form.
